Software M MetaphysicalCells
Friday’s TechBio News
Welcome back to another edition of MetaphysicalCells
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Software M MetaphysicalCells
Welcome back to another edition of MetaphysicalCells
Research
GEN
A new catalog of 1,122 mitochondrial proteins reveals how Acanthamoeba adapts to oxygen loss—and may highlight possible targets for treating sight-threatening infections. The post Proteomics Maps Eye-Infecting <i>Acanthamoeba</i> Mitochondria Across Oxygen Levels appe…
Regulatory F FDA Law Blog
By Steven J. Gonzalez & Peter G. Dickos & Adrienne R. Lenz, Principal Medical Device Regulation Expert —
Software N Nature Medicine
Industry C Cell Systems
Sundar et al. present FLIGHTED, a Bayesian method of accounting for uncertainty in protein fitness measurements by generating probabilistic fitness landscapes from noisy high-throughput experiments. FLIGHTED is applied to selection assays and to a high-throughput base-editing ass…
Industry N Nature Medicine
Clinical N Nature Medicine
Research C Cell Systems
Long et al. integrate single-cell transcriptomes across human embryo development to construct a reference and apply complementary metrics to evaluate four blastoid protocols. The analysis reveals differences in cell identity, developmental timing, and lineage structure, providing…
Industry
BioCentury
BIOCENTURY | GUEST COMMENTARYCHINA BIOPHARMA STILL FACES A LONG ROAD TO GLOBALIZATIONChinese science is already flowing out of the Oktagon. Chinese companies are not. Can this change by 2030?
Industry
BioCentury
BIOCENTURY | FINANCEHIDDEN IN PLAIN SIGHT: CANAAN’S GRANT ON COMPANY BUILDING IN WHITE SPACESJulie Grant joins The BioCentury Show to discuss company building toward M&A, what talent looks like early on, and filling gaps where others aren’t
Funding
BioCentury
BIOCENTURY | FINANCEKALLYOPE BECOMES TRIGEMX, RAISES $94M FOR MIGRAINE THERAPY: VENTURE REPORTPlus: At least four rounds for European biotechs; Link Cell’s series A extension; and more
Industry
BioCentury
BIOCENTURY | DEALSEYEING POST-DUPIXENT YEARS, REGENERON, SANOFI EXPAND IMMUNOLOGY COLLABORATIONThe longtime partners bring four more products into their shared portfolio, including a clinical, long-acting IL-13 inhibitor in Phase I testing
Manufacturing B BioProcess International
An executive for the Boecillo-based CDMO told us how Spain can leverage its strong scientific base to become a manufacturing powerhouse.
Software
Fierce Pharma
How AI-Powered Simulations Help Teams Plan Smarter Studies dwunderlin Thu, 10/01/2026 - 17:13 Thu, 11/19/2026 - 11:00 Resource Type Webinar Rob Buka Luke Mann-O'Halloran Clinical trials rarely unfold exactly as planned. Enrollment shifts, site performance varies, and operational…
Industry
MedCity News
Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029…
Industry
Clinical Trials Arena
This research demonstrates the efficacy of semaglutide for the treatment of obese patients with HF-pEF and type 2 diabetes. The post EASD 2026: Semaglutide shows promise in treating obesity-related heart failure appeared first on Clinical Trials Arena.
Industry
GEN
Researchers found that SLC25A34, a little-studied protein in the mitochondria of fat cells, acts as a switch that connects the body clock, temperature, and diet to how fat cells store and spend energy. The post Mitochondrial Transporter Connects Body Clock and Diet to Fat Burning…
Manufacturing
Fierce Pharma
For biopharma manufacturing at speed and scale, the future is flexible scox Thu, 10/01/2026 - 15:28
Regulatory B BioPharm International
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Industry
Inside Precision Medicine
In the final installment of this series, Riaan and his family face the unknown after five years of developing a genetic medicine for Cockayne syndrome. The post Riaan’s Therapeutic Odyssey – Chapter 5: The Family appeared first on Inside Precision Medicine.
Regulatory
FDA Press Announcements
The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.
Regulatory B BioPharm International
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Regulatory P Pharmaceutical Executive
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Software
GEN
Intrinsically disordered proteins have resisted structure-based drug discovery because they lack a stable fold to model. Talus Bio's structure-free AI model sidesteps that limitation, targeting these proteins in their native environment instead of in isolation or from a predicted…
Industry
Inside Precision Medicine
The frequently used biologic drug mepolizumab may cause an exaggerated inflammatory response in children with severe asthma who carry an incredibly common genetic variant when they contract a viral illness due to a gene–drug interaction. The post Asthma Biologic Interacts with Co…
Industry
BioCentury
BIOCENTURY | DATA BYTELILLY DIFFERENTIATES AGAIN IN AMYLIN RACEEloralintide-tirzepatide combo shows best weight loss yet in obese Type II diabetes patients
Industry P Pharmaceutical Commerce
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Industry
Inside Precision Medicine
Researchers investigated the ability of bat sarbecoviruses to use ACE2 proteins from a broad range of bat and mammalian species. Understanding this interaction could open doors to vaccines and therapeutics. The post SARS-CoV-2 Immunity Broadly Applicable to Related Coronavirus In…
Industry
Fierce Biotech
De-Risk Early or Pay Later Candidate selection is one of the costliest decisions in drug development. See how INDiGO-Select surfaces DMPK, safety and developability risks early, and how INDiGO takes a confirmed candidate to IND with one integrated team. scox Thu, 10/01/2026 - 13:…
Industry
Fierce Pharma
Beyond the Pharmacy Counter: Inmar's Data Advantage pesurya Thu, 10/01/2026 - 12:52
Clinical
Fierce Pharma
Enabling Real-Time Clinical Trials with Imaging Data Real-time clinical trials (RTCT) are becoming a reality as the FDA and HHS pilot programs report data and safety signals in near-real-time. This white paper explores how biopharma companies can prepare for RTCT while safeguardi…
Industry
BioPharma Dive
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.
Clinical A Applied Clinical Trials
The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
Regulatory
BioPharma Dive
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Regulatory
MedTech Dive
The innovation challenge is focused on developing home devices that could help reduce hospital readmissions.
Software T The Niche
I’ve written before about Adeel Khan, who reportedly gave some kind of Muse cells to the Kardashian sisters. Regular readers of The Niche might recall that I’m skeptical about Muse cells. I’ll have a lot more on these cells over the next few weeks. Today I’m focusing on a new vid…
Agriculture
AgriBusiness Global
AI-powered drones are transforming field monitoring, turning aerial data into actionable intelligence that helps agribusinesses prioritize inspections and improve efficiency. The post Beyond Crop Scouting: How AI-Powered Drones Could Reshape Precision Agriculture appeared first o…
Industry
BioPharma Dive
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
Regulatory
MedTech Dive
Medtronic plans to study the device in patients with peripheral artery disease below the knee, a historically difficult condition to treat.